Spark lines up next reti­nal gene ther­a­py pact in Barcelona

When it nabbed the first FDA ap­proval for a reti­nal gene ther­a­py in 2017, Spark Ther­a­peu­tics helped launch a field of biotechs look­ing to treat eye dis­eases with a one-and-done med­i­cine. No oth­er reti­nal gene ther­a­py biotech has fol­lowed in its reg­u­la­to­ry foot­steps since, but a co­hort of star­tups in the field have emerged, giv­ing Roche-owned Spark a litany of part­ner­ing op­tions.

Its lat­est part­ner of choice is Barcelona biotech Splice­Bio, whose pro­tein splic­ing am­bi­tions could lead to the de­liv­ery of large genes in parts. Based off work out of Prince­ton, Splice­Bio is tak­ing a dif­fer­ent ap­proach to AAV gene ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER